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Abstract
Background: Cell lines are used in experimental investigation of cancer but their capacity to
represent tumor cells has yet to be quantified. The aim of the study was to identify significant
alterations in pathway usage in cell lines in comparison with normal and tumor tissue.
Methods:  This study utilized a pathway-specific enrichment analysis of publicly accessible
microarray data and quantified the gene expression differences between cell lines, tumor, and
normal tissue cells for six different tissue types. KEGG pathways that are significantly different
between cell lines and tumors, cell lines and normal tissues and tumor and normal tissue were
identified through enrichment tests on gene lists obtained using Significance Analysis of Microarrays
(SAM).
Results: Cellular pathways that were significantly upregulated in cell lines compared to tumor cells
and normal cells of the same tissue type included ATP synthesis, cell communication, cell cycle,
oxidative phosphorylation, purine, pyrimidine and pyruvate metabolism, and proteasome. Results
on metabolic pathways suggested an increase in the velocity nucleotide metabolism and RNA
production. Pathways that were downregulated in cell lines compared to tumor and normal tissue
included cell communication, cell adhesion molecules (CAMs), and ECM-receptor interaction. Only
a fraction of the significantly altered genes in tumor-to-normal comparison had similar expressions
in cancer cell lines and tumor cells. These genes were tissue-specific and were distributed sparsely
among multiple pathways.
Conclusion: Significantly altered genes in tumors compared to normal tissue were largely tissue
specific. Among these genes downregulation was a major trend. In contrast, cell lines contained
large sets of significantly upregulated genes that were common to multiple tissue types. Pathway
upregulation in cell lines was most pronounced over metabolic pathways including cell nucleotide
metabolism and oxidative phosphorylation. Signaling pathways involved in adhesion and
communication of cultured cancer cells were downregulated. The three way pathways comparison
presented in this study brings light into the differences in the use of cellular pathways by tumor cells
and cancer cell lines.
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Background
Cell lines derived from tumors and tissues comprise the
most frequently used living systems in research on cell
biology. Limitations on the abundance of tissue samples
necessitate the use of animal models and cell lines in the
studies of tumor-related phenomena. Cancer cell lines
have been extensively used in screening studies involving
drug sensitivity and effectiveness of anti cancer drugs [1].
Other studies using cultured cells aimed at the determina-
tion of the phenotypic properties of cancer cells such as
proliferation rates, migration capacity and ability to
induce angiogenesis [2]. In other studies, human cultured
cells were used to create tumors in the mice models [3].
Whether measurements on cell lines provide information
about the metastatic behavior of cancer cells in vivo is cur-
rently under investigation. Unsupervised classification of
gene expression profiles of cancer tissue and cancer cell
lines result in separate clustering of cancer cell lines from
tissue cells for both solid tumors and blood cancers [4].
Sets of genes responsible for differences between solid
tumors and cell lines in their response to anti cancer drugs
have been identified in the Serial Analysis of Gene Expres-
sion (SAGE) Database [5]. Most optimal cell lines to rep-
resent given tumor tissue types were determined with the
use of a quantitative tissue similarity index [6]. Results
were striking: only 34 of the 60 cell lines used in the anal-
ysis were most similar to the tumor types from which they
were derived. The study provided valuable information
about selection of most appropriate cell lines in pharma-
ceutical screening programs and other cancer research. In
a more recent work Sandberg et al. [7] identified those
gene function groups for which cell lines differed most
significantly from tumors based on meta-analysis using
Gene Ontology (GO). Genes involved in cell-cycle pro-
gression, protein processing and protein turnover as well
as genes involved in metabolic pathways were found to be
upregulated (an increase in expression reflected by mRNA
transcript levels) in cell lines, whereas genes for cell adhe-
sion molecules and membrane signaling proteins in cell
lines were downregulated (a decrease in expression
reflected by mRNA transcript levels) in comparison with
tumors [7]. To build on this approach, functional enrich-
ment analysis based on Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathways [8,9] can be used to illustrate
causal relationships between genes (gene products).
While GO is organized into hierarchical annotations in
the context of normal cellular function, the KEGG data-
base organizes the genes (gene products) into pathway
reaction maps and functional complexes, including some
disease-specific pathways.
The present study focuses on pathway specific differences
in gene expression patterns between cancer cell lines and
tumors as well as cancer cell lines and normal tissue and
tumors and normal tissue. Extension of microarray data
analysis to three-way comparison allows for the identifi-
cation of gene expression patterns unique to cell lines.
Such patterns might have arisen due to factors related to
the cell culture environment. We used publicly accessible
microarray data available for normal and cancer tissues
and associated NCI60 cell lines in a pathway-specific
quantitative analysis of gene expression profiles. A domi-
nant theme that emerged from our analysis was that path-
way-specific gene expression differences between cancer
cell lines and cancer tissue were similar both in magnitude
and direction to corresponding differences between cell
lines and normal tissue cells. Cell cycle associated differ-
ences between normal and tumor tissue were amplified in
cell lines. Results on metabolic pathways suggested an
increase in the velocity of RNA and DNA production and
increased flow of metabolites in the oxidative phosphor-
ylation pathway. On the other hand, a small fraction of
significantly altered genes in tumor-to-normal compari-
son had similar expressions in cancer cell lines and tumor
cells. These genes were tissue-specific and were positioned
sparsely along multiple pathways.
Materials and methods
Microarray datasets
Microarray datasets used in this study consisted of the
publicly accessible gene expression profile dataset for
NCI60 cell lines [10] and similar data for a panel of
tumors and normal tissue samples [11]. This dataset con-
tains measurements obtained using the Affymetrix
Hu6800 arrays (Table 1). The tissue types considered in
this study (breast, CNS, colon, prostate, ovary, and renal
tissue) were restricted to those where the microarray
results were available for normal and tumor tissue as well
as corresponding cell lines. MDA-MB-435 and MDN cell
line samples were excluded from these datasets because
their tissue of origin, previously thought to be breast, is
now suspect [6].
Quality of probe set annotations
Quality of the Hu6800 GeneChip annotation was
assessed because this platform is several versions away
from current human microarrays. While the Hu6800
design is old and probe designs have since been greatly
improved, the quality of probe annotation is maintained
through regular updates by Affymetrix. The annotations
used in this study are based on a July 12th 2006 update of
Affymetrix annotations according to the March 2006
(NCBI Build 36.1) version of the human genome. A com-
parison was done between gene annotations for the
Hu6800 GeneChip obtained from Webgestalt (web-based
gene set analysis toolkit) [12] and from the Affymetrix
website on August 7th, 2006. Out of the 7129 probesets on
the chip, 6058 had the same annotations from both Web-
gestalt and Affymetrix. Of the remaining 1071 probesets,Molecular Cancer 2006, 5:55 http://www.molecular-cancer.com/content/5/1/55
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692 were not annotated, 288 were annotated in the
Affymetrix list but not in Webgestalt, 28 were annotated
in Webgestalt but not Affymetrix, and 63 (~1%) probesets
had conflicting annotations in Webgestalt and Affymetrix.
Only 42 (~0.70% of all genes) genes belonging to any
known KEGG pathway had discrepancies between Webge-
stalt and Affymetrix. While there were very few probes
with discrepant annotations in any given pathway, this list
of 42 probes was enriched for Antigen processing and
presentation, Natural killer cell mediated cytotoxicity,
Cell adhesion molecules (CAMs), Type I diabetes melli-
tus, and SNARE interactions in vesicular transport path-
ways. A review of this probe list revealed that
discrepancies were merely due to updates and minor revi-
sions to the official gene symbol that may reflect increased
understanding of these genes functions. Genes associated
with KEGG pathways represent a subset of well-studied
and sequenced genes. Overall, the probe sets of genes
belonging to KEGG pathways have well established and
reliable annotations on the Hu6800 GeneChip. Annota-
tions retrieved from Webgestalt were used for the remain-
der of the analysis.
Normalization
Gene expression data was normalized for each tissue type
by computing the Robust Multichip Average (RMA)
[13,14] directly from the Affymetrix .CEL files for cell line,
tumor, and normal samples. RMA consists of three steps:
a background adjustment, quantile normalization and
finally summarization. Quantile normalization method
utilizes data from all arrays in an experiment in order to
form the normalization relation [13,14] RMA generated
expression measure is on the log base 2 scale.
Normalized data was generated using the Bioconductor
(package for R) [15] implementation of RMA. R 2.3.1 [16]
was first installed on an Intel Xeon machine running a
Windows Professional Operating System. The Biobase
1.10.1 (dated 20 June 2006) package which contains the
base functions for Bioconductor was installed by access-
ing the getBioC.R script directly from the Bioconductor
website [17]. The "readaffy" command was used to load
all .CEL files for a single tissue type. The RMA expression
measures for each tissue type were computed using the
"rma" function with default settings, including the Perfect
Match Adjustment Method setting as Perfect Match Only
so that expression signal calculation was based upon the
perfect match values from each probe set as described in
[13]. The RMA computed expression values were written
out to a comma separated text file.
The resulting expression values for each sample were
checked against the average expression across cell line,
tumor, and normal populations by calculating their corre-
lation coefficients. Two anomalous samples (one normal
tissue sample from colon and one tumor sample from
prostate) were identified having correlations well outside
the remaining population (R < 0.9) and removed; RMA
for those tissues was recomputed excluding the suspect
samples. The RMA generated gene expression data for the
Affymetrix chips was clustered using a hierarchical cluster-
ing algorithm with Pearson correlation coefficient as the
distance metric using average linkage using TIGR MeV
Version 3.1. For each of the six tissues under considera-
tion, the cell line samples clustered together in a single
branch distinct from the branches containing tumor and
normal tissue samples. This result confirmed that all the
cell line samples have characteristics that are significantly
different from the tumor tissue.
Significance analysis for gene expression
The Significance Analysis of Microarray Data (SAM)
implementation [18] in the TIGR MeV Version 3.1 soft-
ware [19] was used to identify those genes that had statis-
tically significant differences in expression between tumor
samples, cell lines, and normal tissue. SAM analysis was
performed using all default parameters and adjusting the
delta-value to obtain a maximum number of genes while
Table 1: Microarray data presented by Staunton et al. [10] and Ramaswamy et al. [11] used in the three way comparison of gene 
expression patterns in cell lines, tumors and normal tissue.
Cell lines* Normal tissue** Tumor tissue** Array
Breast 6 5 10 Affymetrix
CNS 6 5 20 Affymetrix
Colon 7 10 9 Affymetrix
Ovary 649 A f f y m e t r i x
Prostate 277 A f f y m e t r i x
Renal 8 11 8 Affymetrix
Sum 35 42 63
* Data obtained from Staunton et al [10]
** Data obtained from Ramaswamy et al [11]Molecular Cancer 2006, 5:55 http://www.molecular-cancer.com/content/5/1/55
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maintaining a conservative false discovery rate of zero. A
list of significant genes was identified for cell line-tumor
cell line-normal and normal-tumor combinations for
each of the six tissue types. When the set of significant
genes was deleted from the microarray data, clustering
analysis based on the remaining genes interspersed micro-
array datasets for cell lines with corresponding datasets for
tissue.
Identification of significantly altered pathways
Two different methods were used for identifying signifi-
cantly altered pathways. First, Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathways [8,9] were identi-
fied as significantly altered by performing a functional
enrichment analysis on genes identified as significant by
SAM analysis. The analysis was carried out using the Web-
gestalt system [12], comparing significant genes obtained
by SAM against all genes in the Affymetrix HU6800 array,
for each comparison under study. A p-value for pathway
enrichment was obtained using the hypergeometiric test
documented in [12]. Four different p-value cutoffs (0.001,
0.01, 0.05 and 0.1) were used in order to assess the
dependence of the significant pathway identification on p
value. This process was also applied to subsets of signifi-
cant genes, for example, the intersection of significant
genes from (CL - N) and (T - N).
A second method was applied to KEGG pathway genes in
order to detect changes that were not apparent on a single-
gene basis. For this method, KEGG pathways were
deemed significantly altered if at least 80% of the genes
for that pathway contained on the HU6800 array were
shifted in the same direction for a given comparison. For
each of the six tissues, three-way comparisons were per-
formed between averaged cell line, tumor, and normal
samples. Similar examples of how significant changes in
functional pathways are revealed by a population of
related genes that are not evident from observations of a
single gene are found in [20,21].
Results
Significant genes
This article presents a pathway-specific analysis of gene
expression profile differences between cancer cell lines
and normal and tumor tissue. The microarray data used in
the three-way comparison of gene expression profiles cov-
ered breast, CNS, colon, ovary, prostate, and renal tissue
(Table 1). Gene expression profiles of cancer cell lines
derived from this data clustered together in a branch
exclusive of tumor and normal tissue (3) within each tis-
sue type and for all tissue types combined. Lists of signifi-
cant genes (SAM genes) were determined using SAM
analysis from the microarray data pairs of cell lines and
tumors (CL - T), cell lines and normal tissue (CL - N) and
tumor and normal tissue (T - N) for each of the six tissue
types under consideration. Table 2 provides a summary of
the numbers of significant genes for the three-way com-
parison. The table shows that the significant genes for (CL
- T) and (CL - N) pairs ranged in numbers from low hun-
dreds to thousands, depending on the tissue type. Signifi-
cant genes for (T - N) pairs were lower in number than
those for (CL - T) and (CL - N) pairs in all six tissues under
consideration. Downregulation of significant genes was a
trend in (T - N) comparisons while a majority of SAM
genes were upregulated in cell lines compared to tumor
and normal (CL - T; CL - N). Moreover, an overwhelming
majority of the SAM genes in (T - N) comparison were not
found as significantly altered in (CL - T) comparisons. The
gene set (T - N) - (T - N ∩ CL - T) listed in Table 2 shows
a vast majority of SAM genes in (T - N) comparison are not
significantly altered in expression in (CL - T) comparison,
suggesting that cancer cell lines may be good representa-
tion models for tumor cells in gene expression profile
studies. On the other hand, the set (CL - T) contains many
more genes than the (T - N) comparison, revealing that
cancer cell lines have a large number of genes that are sig-
nificantly altered in expression compared to tumor cells.
The same trend holds true when cell lines are compared
with normal tissue cells. These results indicate that global
gene expression profiles of cultured cancer cell lines con-
tain significantly different gene expression patterns com-
pared to the corresponding profiles for normal and tumor
tissue.
SAM genes common in (CL - T) comparisons for all six tis-
sues were all upregulated. Table 3 shows the list of 51 sig-
nificant genes in (CL - T) comparisons that are common
to the six tissue types under consideration. In this list of 51
genes, the overrepresented KEGG pathways with a p-value
cutoff of 0.01 are cell cycle, oxidative phosphorylation,
proteasome, pyrimidine metabolism, and ubiquitin
mediated proteolysis. The 18 genes shown in italics also
appeared among 29 significant genes that were common
to all (CL - N) comparisons. The 18 genes common to
both lists again showed overrepresentation of cell cycle
and ubiquitin mediated proteolysis pathways under a p-
value cutoff of 0.01. Moreover these eighteen genes
showed the same trend of upregulation in cell line-to-
tumor (CL - T) and cell line-to-normal (CL - N) compari-
sons. No significant genes identified in the (T - N) com-
parisons were common to all six tissues.
Significant pathways
KEGG pathways whose gene expression profiles differed
significantly in (CL - T), (CL - N), and (T - N) pair compar-
isons were identified using a hypergeometric test as
described in the Methods section. Figure 1 shows the most
frequently observed KEGG pathways with altered gene
expression profiles for (CL - T), (CL - N) and (T - N) pairs
for breast, CNS, colon, ovary, prostate, and renal tissue.Molecular Cancer 2006, 5:55 http://www.molecular-cancer.com/content/5/1/55
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Cell cycle and a number of metabolic and transcription-
related pathways emerged as significantly altered in
almost all (CL - T) and (CL - N) comparison pairs. Cellular
pathways that were significantly altered in cell lines com-
pared to tumor cells and normal cells of the same tissue
type in at least two tissue types included cell cycle, oxida-
tive phosphorylation, purine and pyrimidine metabo-
lism, proteasome, ribosome, and RNA polymerase. The
most striking difference between cell lines and tumor tis-
sue in Figure 1 is in the oxidative phosphorylation path-
way. Oxidative phoshorylation is the final stage of cellular
metabolism following glycolysis and the citric acid cycles.
The loss of cancer cell dependence on oxidative metabo-
lism may be an important factor in the development of
tumors [22]. ECM-receptor interaction, which is thought
to affect cell migration, appeared with more subtle differ-
ences between all comparisons (CL - T), (CL - N), and (T
- N). This may reflect more tissue-specific composition of
the migration machinery utilized in tumor cell invasion.
Next we used pathway-specific analysis to identify up- and
downregulation patterns in three-way comparisons. Fig-
ure 2 provides module maps showing the direction of reg-
ulation of KEGG pathways that were identified to be
significantly different in at least 2 tissue types in (CL - T)
comparisons. The pathways presented in Figure 2a were
deemed significantly altered if the average gene expression
between two conditions was altered in the same direction
for at least 80% of the genes in the pathway. This criterion
captured seven of the significant pathways from Figure 1
along with 23 additional pathways. The Figure 2a indi-
cates a high degree of correlation in the direction of Ami-
noacyl-tRNA synthetases, Monoterpenoid biosynthesis,
Proteosome, and RNA polymerase pathway shifts in cell
line – tumor and cell line – normal comparisons. Many
more pathways appear to be significantly altered in the
module map if the criterion for percentage of genes
altered in the same direction is reduced from 80% to 70%
(Figure 2b). These two module maps illustrate how exten-
sive the pathway alterations are in cell lines compared to
tumor and normal tissue (CL - T; CL - N).
The pathway-specific results on cell line-tumor microarray
data comparisons presented in this study are in agreement
with the results recently published by Sandberg et al. [7]
on the gene expressions patterns associated with gene
ontology categories in cell lines and tumors. These
authors have used the same microarray databases used in
our study and reached highly similar conclusions on the
directions of difference between cell lines and tumors
along equivalent pathways and gene ontology categories.
Table 4 provides a comparison of the KEGG pathways
(from Figure 1) against the most related gene ontology
categories from Sandberg et al. [7]. KEGG pathways for
complement and coagulation cascade and phenylalanine
metabolism passed the significance criteria based on the
(T - N) comparison in our study but we could not located
the corresponding GO categories in the Sandberg et al.
study on cell lines vs. tumor tissue.
Gene expression changes in metabolic pathways
Metabolic pathways such as oxidative phosphorylation,
pyrimidine and purine metabolism account for some of
the most significant alterations among the three-way com-
parisons. The alterations in the oxidative phosphorylation
pathway were discussed briefly in the previous section.
Purine and pyrimidine metabolic pathways synthesize the
nucleotides that make RNA and DNA. All of the nitrogens
in the purine and pyrimidine bases (as well as some of the
carbons) are derived from amino acids glutamine, aspartic
acid, and glycine, whereas the ribose and deoxyribose sug-
ars are derived from glucose. Figure 3 shows the KEGG
diagram of pyrimidine metabolism with the expression
values (averaged over six tissues) overlaid for (CL - T)
(3a), (CL - N) (3b), and (T - N) (3c) comparisons. This
KEGG pathway is altered with upregulated expression for
Table 2: Number of significant genes identified by SAM in comparisons of cell line-to-tumor (CL - T), cell line-to-normal (CL - N), and 
tumor-to-normal (T - N) comparisons.
Comparison Breast CNS Colon Ovary Prostate Renal Common Genes
CL-T (upregulated %) 572 (66%) 576 (86%) 503 (62%) 603 (41%) 190 (94%) 1637 (44%) 51
CL-N (upregulated %) 269 (61%) 560 (72%) 983 (63%) 225 (62%) 469 (72%) 2047 (45%) 29
T-N (upregulated %) 243 (10%) 153 (61%) 166 (45%) 94 (14%) 30 (0%) 65 (0%) 0
CL-T ∩ CL-N 132 328 431 145 164 1481 16
(T-N) - (T-N ∩ CL-T) 236 138 143 83 26 43 0
(T-N ∩ CL-N) - (T-N ∩ CL-N ∩ CL-T) 31 43 64 26 9 28 0
The percentage of upregulated genes is shown in parentheses for cell line-to-tumor (CL - T), cell line-to-normal (CL - N), and tumor-to-normal (T 
- N) comparisons. The intersection (CL - T ∩ CL - N) contains genes that were altered in cell lines compared to both normal and tumor tissue, 
representing expression profiles that are specific to cell lines. The set (T - N) - (T - N ∩ CL - T) contains SAM genes in the (T - N) comparisons that 
are not significantly altered in (CL - T) comparisons. The set (T - N ∩ CL - N) - (T - N ∩ CL - N ∩ CL - T) contains genes significantly altered in 
both cell lines and tumors relative to normal tissue (T - N; CL - N) but with no significant difference between cell lines and tumor tissue (CL - T); 
tumor-specific expression profiles that may be adequately modeled by cell lines.M
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Table 3: SAM genes that were upregulated in cell lines compared to tumors in all the 6 tissues considered in the study (CL - T).
Gene Symbol Gene Name Kegg Pathway(s)
ATP5B ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide Oxidative phosphorylation, ATP synthesis
ATP5G3 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit C3 (subunit 9) ATP synthesis, Oxidative phosphorylation
C1QBP complement component 1, q subcomponent binding protein (Immune Response)
CBX3 chromobox homolog 3 (HP1 gamma homolog, Drosophila) N/A
CCNB1 cyclin B1 Cell cycle
CCT5 chaperonin containing TCP1, subunit 5 (epsilon) N/A
CDC20 CDC20 cell division cycle 20 homolog (S. cerevisiae) Ubiquitin mediated proteolysis, Cell cycle
CDKN3 cyclin-dependent kinase inhibitor 3 (CDK2-associated dual specificity phosphatase) N/A
CHAF1A chromatin assembly factor 1, subunit A (p150) N/A
CKAP1 cytoskeleton associated protein 1 N/A
CKS1B CDC28 protein kinase regulatory subunit 1B N/A
CKS2 CDC28 protein kinase regulatory subunit 2 N/A
COX8A cytochrome c oxidase subunit 8A (ubiquitous) Oxidative phosphorylation
CYC1 cytochrome c-1 Oxidative phosphorylation
DNMT1 DNA (cytosine-5-)-methyltransferase 1 Methionine metabolism
DYNLL1 dynein, light chain, LC8-type 1 N/A
EBNA1BP2 EBNA1 binding protein 2 N/A
HMGB2 high-mobility group box 2 N/A
KIAA0101 KIAA0101 N/A
KIF2C kinesin family member 2C N/A
LMNB2 lamin B2 Cell communication
MCM3 MCM3 minichromosome maintenance deficient 3 (S. cerevisiae) Cell cycle
MCM4 MCM4 minichromosome maintenance deficient 4 (S. cerevisiae) Cell cycle
MCM7 MCM7 minichromosome maintenance deficient 7 (S. cerevisiae) Cell cycle
MRPL12 mitochondrial ribosomal protein L12 N/A
NDUFS8 NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa (NADH-coenzyme Q reductase) Oxidative phosphorylation
PAICS phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase Purine metabolism
PCNA proliferating cell nuclear antigen Cell cycle
POLR2G polymerase (RNA) II (DNA directed) polypeptide G Purine metabolism, RNA polymerase, Pyrimidine metabolism
PRMT1 protein arginine methyltransferase 1 Selenoamino acid metabolism, Nitrobenzene degradation, Aminophosphonate 
metabolism, Tryptophan metabolism, Histidine metabolism, Androgen and 
estrogen metabolism, Tyrosine metabolism
PSMA1 proteasome (prosome, macropain) subunit, alpha type, 1 Proteasome
PSMB2 proteasome (prosome, macropain) subunit, beta type, 2 Proteasome
PSMB5 proteasome (prosome, macropain) subunit, beta type, 5 Proteasome
PSMB6 proteasome (prosome, macropain) subunit, beta type, 6 Proteasome
PSMD14 proteasome (prosome, macropain) 26S subunit, non-ATPase, 14 Proteasome
RANBP1 RAN binding protein 1 N/A
SFRS9 splicing factor, arginine/serine-rich 9 N/A
SNRPA small nuclear ribonucleoprotein polypeptide A N/A
SNRPB small nuclear ribonucleoprotein polypeptides B and B1 N/A
SNRPC small nuclear ribonucleoprotein polypeptide C N/A
SNRPD2 small nuclear ribonucleoprotein D2 polypeptide 16.5kDa N/A
SNRPD3 small nuclear ribonucleoprotein D3 polypeptide 18kDa N/A
SNRPE small nuclear ribonucleoprotein polypeptide E N/A
SNRPF small nuclear ribonucleoprotein polypeptide F N/A
SNRPG small nuclear ribonucleoprotein polypeptide G N/A
TCEB1 transcription elongation factor B (SIII), polypeptide 1 (15kDa, elongin C) Ubiquitin mediated proteolysis
TUBG1 tubulin, gamma 1 N/A
TXNRD1 thioredoxin reductase 1 Pyrimidine metabolism
TYMS thymidylate synthetase Pyrimidine metabolism, One carbon pool by folate
UBE2C ubiquitin-conjugating enzyme E2C Ubiquitin mediated proteolysis
UBE2S ubiquitin-conjugating enzyme E2S N/A
SAM genes shown in italic also belonged to cell lines and normal tissue comparison. There were no downregulated genes common to all tissue types in cell line-tumor (CL - T) comparisons.Molecular Cancer 2006, 5:55 http://www.molecular-cancer.com/content/5/1/55
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a majority of genes in cell lines and tumors when com-
pared to normal tissue. The increased levels of pyrimidine
metabolism gene expression are most pronounced in cell
lines (Fig 3a). A predicted increase in the velocity of RNA
and DNA base production in cell lines is consistent with
trends of increasing rates of cell division observed in cell
cultures [23]. The observation that nucleotide metabo-
lism accelerates in cancer has been discussed in the litera-
ture. Development of pyrimidine and purine analogs as
potential antineoplastic agents evolved from an early pre-
sumption that cancer is a disease of uncontrolled growth
and nucleic acids are involved in growth control [24].
Gene expression pattern changes in cell cycle
In contrast to the pyrimidine metabolism pathway dis-
cussed above, the gene expression alterations along the
cell cycle pathway appear to be more complex and tissue-
specific. Figure 4a shows the KEGG diagram of cell divi-
sion cycle with genes specific to Homo sapiens shaded
light green. Figure 4b shows the extent of alteration of
these genes in the three-way comparisons for each tissue
type with a graded color map representing maximum
upregulation in red and maximum downregulation in
green.
Perhaps the most obvious feature of this color map is how
subtle the changes in (T - N) comparisons are relative to
(CL - T) and (CL - N) comparisons in all six tissues under
consideration. Genes such as CCNA2, CCNB1, CDC20,
CDK4, and MDM2 through MDM7 are consistently
upregulated in cell lines compared to tumors and normal
tissue. On the other hand, genes such as CCND1, CCND3,
CDC16, and CDK2 do not exhibit quickly a recognizable
pattern. A multitude of gene expression profiles in cell
cycle may point towards the same disease process.
SAM genes common to cancer cell lines and tumor cells
It is of interest to cell biologists to identify similarities
between cancer cell lines and tumors. Towards that goal,
one can determine the list of SAM genes belonging to both
(T - N) and (CL - N) comparisons but do not appear to be
significant in (CL - T) comparison. This list is shown in
Table 5 for all six tissues under consideration. Table 5
gives an indication of the size of the SAM gene subsets that
are preserved and commonly regulated in cell lines and
tumors but not in normal tissues. The list of genes in Table
5 comprises mostly downregulated genes for breast,
colon, ovary, prostate, and renal tissue, with CNS as the
only exception. When these lists were projected onto
KEGG pathways, the probability of enrichment score
could not be used as an indication that the pathways are
KEGG pathways identified to be significantly altered in cell lines and tumors (CL - T), cell lines and normal tissue (CL - N), and  tumor and normal tissue (T - N) comparisons Figure 1
KEGG pathways identified to be significantly altered in cell lines and tumors (CL - T), cell lines and normal tis-
sue (CL - N), and tumor and normal tissue (T - N) comparisons. The term frequency shown in the figure is defined as 
the ratio of tissue types for which a pathway identified as significantly altered to the total number of tissue types (6). KEGG 
pathways were identified as significantly altered by using a hypergeometric test with a p-value cutoff. The minimum number of 
SAM genes in each significantly altered pathway has been set to two. The error bars indicate the standard deviation of fre-
quency for different p- value cutoffs (p = 0.001, 0.01, 0.05 and 0.1).
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A module map showing the direction of regulation of cellular pathways that were identified as significantly altered in cell lines  compared to tumor tissue (CL - T) in at least 2 of the 6 tissues considered in this study Figure 2
A module map showing the direction of regulation of cellular pathways that were identified as significantly 
altered in cell lines compared to tumor tissue (CL - T) in at least 2 of the 6 tissues considered in this study. In 
(a), a pathway is deemed significantly altered if at least 80% of the genes in the pathway are shifted in a common direction. In 
(b), a pathway is deemed significantly altered if at least 70% of the genes in the pathway are shifted in a common direction. The 
color red indicates an upregulated pathway, the color green indicates a downregulated pathway, and the color black indicates 
that the pathway was not significant in that comparison.
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similar because KEGG pathways that include genes from
these lists also included SAM genes from (CL - T) compar-
isons. In conclusion, it was not possible to assert pathway
similarity with statistical confidence using this analysis.
Conclusion
Our study shows that a large portion of genes implicated
in the emergence and progression of cancer have similar
gene expression values in tumors and cancer cell lines
indicating the value of cultured cell lines in cancer
research. However, the pair-wise comparisons of gene
expression profiles of CL, T, and N across all tissues illus-
trate that there are pronounced changes in gene expres-
sion specific to cell lines (CL - T; CL - N) that may not
represent a disease process. This study also identified the
signaling and metabolic pathways in cell lines that have
distinctly different gene expression patterns than those
associated with normal and tumor tissue. Pathway-spe-
cific gene expression changes in (CL - T) and (CL - N)
comparisons were more consistent than (T - N) compari-
sons in the set of six tissues under consideration. Just as
the gene expression changes in tumor – normal tissue
comparison were largely tissue-specific, the significantly
altered pathways among tumor – normal comparisons
were limited to a small number of tissues. Functional
enrichment analysis allows us to explore significant
changes in pathways despite having heterogeneous
changes in gene expression across different tissues. Cellu-
lar pathways that were significantly upregulated in cell
lines compared to tumor cells and normal cells of the
same tissue type included ATP synthesis, cell cycle, oxida-
tive phosphorylation, purine, pyrimidine and pyruvate
metabolism, and proteasome. Results on metabolic path-
ways suggested an increase in the velocity nucleotide
metabolism and RNA production.
The dominant trend in the gene expression profiles along
significantly altered pathways in cell lines appeared to be
upregulation of genes when compared either to tumor or
normal tissue. Exceptions included genes in the cell adhe-
sion molecules, cell communication, and ECM-receptor
interaction, focal adhesion, and complement/coagulation
cascade pathways. The apparent downregulation of the
complement/coagulation cascade in cell lines may be due
to the heterogeneous mixture of cells in tumor samples
including immune cells as well as tissue-specific cells.
The composition of the cell culture medium may be the
reason why gene expression patterns that differentiate
cancer cell lines from tumor tissue are similar to those pat-
Table 4: Comparison of results obtained from this study with those based on Gene Ontology Processes by Sandberg et al. [7]
KEGG Pathway Related GO category Direction of regulation in cell lines with respect to tumors
This study Gene Ontology Study [7]
ATP synthesis ATP synthesis coupled proton 
transport (GO:0015986)
↑↑
Cell cycle Cell cycle (GO:0007049) ↑↑
One carbon pool by folate Nucleotide biosynthesis 
(GO:0009165)
↑↑
Oxidative phosphorylation Oxidative phosphorylation 
(GO:0006119)
↑↑
Proteasome Ubiquitin-dependent protein 
catabolism (GO:0006511); 
Modification-dependent protein 
catabolism (GO:0019941)
↑↑
Purine metabolism Purine nucleotide metabolism 
(GO:0006163)
↑↑
Pyrimidine metabolism Nucleobase, nucleoside, nucleotide 
and nucleic acid metabolism 
(GO:0006139)
↑↑
Ribosome Protein biosynthesis (GO:0006412) ↑↑
RNA polymerase Nucleobase, nucleoside, nucleotide 
and nucleic acid metabolism 
(GO:0006139)
↑↑
Cell adhesion molecules (CAMs) Cell adhesion (GO:0007155) ↓↓
Cell communication Cell adhesion (GO:0007155) ↓↓
Complement and coagulation cascade Complement activation (GO:0006956) ↓ N/A
ECM-receptor interaction Cell adhesion (GO:0007155) ↓↓
Focal Adhesion Cell adhesion (GO:0007155) ↓↓
Phenylalanine metabolism Phenol metabolism (GO:0018958) ↓ N/A
The symbol [↑] indicates upregulation in cell lines with respect to tumors and [↓] indicates downregulation in cell lines with respect to tumors (CL 
- T).Molecular Cancer 2006, 5:55 http://www.molecular-cancer.com/content/5/1/55
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KEGG pyrimidine metabolism diagram Figure 3
KEGG pyrimidine metabolism diagram. Gene expression shifts are projected from comparisons of cell line-to-tumor 
(CL - T), cell line-to-normal (CL - N), and tumor-to-normal (T - N) comparisons averaged over all six tissues. The color red 
indicates upregulated genes, green indicates downregulated genes and grey indicates the genes that are not on the microarray. 
Uncolored genes are not in the organism-specific pathway for Homo sapiens. A gene is identified as upregulated (downregu-
lated) if its gene expression value averaged over 6 tissue types were greater (or lesser) in cell lines compared to tumor or nor-
mal tissue. Colored genes with white lettering were also identified with SAM in at least two tissues.
A. (CL – T) 
B. (CL – N)  C. (T – N) Molecular Cancer 2006, 5:55 http://www.molecular-cancer.com/content/5/1/55
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KEGG cell cycle diagram Figure 4
KEGG cell cycle diagram. Genes are shown (a) in a pathway map with genes specific to homo-sapiens shaded light green 
and (b) tabulated with a color map showing average gene expression shifts for samples within the six tissues. Red indicates a 
positive change and green indicates a negative change in average RMA value for the respective cell line-tumor (CL - T), cell line-
normal (CL - N), and tumor-normal (T - N) comparisons, with color scale limits set to -2 and +2.
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Table 5: Genes that were identified by SAM in both (T - N) and (CL - N) comparisons but not in (CL - T) comparisons; (T - N ∩ CL - N) 
– (T - N ∩ CL - N ∩ CL - T).
Breast CNS Colon Ovary Prostate Renal
UP DOWN UP DOWN UP DOWN UP DOWN UP DOWN UP DOWN
GALNS APP ACTB ATP5O ARD1A ADH1B MCM2 ACTG2 APOD ADH1B
GP9 AQP1 CPSF1 COX7A1 ARPC1B BRD2 AEBP1 CCND2 ALDH4A1
LCAT ARHGEF6 DDX11 CTNNB1 BCAT1 C7 C7 CXCL12 ANPEP
RND2 ATP6V1B2 ECE1 GYPE CCND1 CA2 CEBPD KCNMB1 ASS
BRD2 EEF1A1 ITGB7 CPNE1 CALCOCO2 CNN1 MATN2 ATP6V1B1
CTNNB1 EEF1G KIAA0513 CUL7 CASC3 DPYSL2 PTGDS C7
CXCL12 FRAP1 MEF2C ERCC1 CES2 DUSP1 PTN CLCNKB
DUSP1 GNAI2 MRPS21 GPS1 CHGA EGR1 SERPING1 ENG
EGR1 GNB1 MYOM2 MDK CLEC3B FOS SPARCL1 EPHX2
EGR3 GNB2 PCP4 PDXK CNN1 GYPC FABP1
IGFBP4 GPIAP1 PVALB PEX6 CRYAB IGFBP5 GATA3
JUND GPS1 S100A1 PHLDA2 CTNNB1 JUNB GATM
KHSRP H3F3B SEPP1 S100A11 CUGBP2 LMOD1 GPX3
KIT HNRPF SERPINI1 TEAD4 DMD LUM GSTA2
KRT15 KHDRBS1 DPYSL2 MYH11 HMGCS2
KRT5 MAZ FABP4 MYLK HPD
MXI1 NONO FCGBP NDN KCNJ1
MYH11 ODC1 FGFR2 NR4A1 MT1G
NFIB PCBP2 FHL1 PPAP2B MT1X
NSMAF RAB7 GDI1 SEPP1 PAH
PCBP1 RBM10 GPD1L SERPINF1 PALM
SERPINA3 RBM5 HMGCS2 SPARCL1 PCK2
SNTB2 RHOB HSD11B2 TNXB PRODH2
SOX9 SMARCA4 HSPA1A ZBTB16 PTHR1
SPARCL1 SRM IL11RA ZFP36 SERPINA5
VWF TRIM28 IL6R TACSTD1
ZFP36 TUBB ITGA7 UGT2B7
UFM1 ITPKB UMOD
YBX1 LMOD1
LPL
MAOA
NFIB
NR3C2
PCK1
PLN
PPAP2B
PPP1R1A
PRKCB1
SEPP1
SLC26A3
SMTN
SPIB
SRPX
TACR2
TGFBR3
TPM1
TPM2
TSPAN7
TUBA3
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terns that differentiate between cell lines and normal tis-
sue. Typical cell culture medium is replete with
metabolites, growth factors, and cytokines, among others,
for which cells normally must compete in vivo [24]. Mul-
ticellular interfaces with which tumor cells interact in vivo
are not replicated for cells grown in cell culture plates [26-
29]. The differences in environmental selection pressures
may help explain the differential gene expression patterns
between the tumor tissue and the cell lines. Our finding
about the upregulation of oxidative phosphorylation in
cell lines is supported by previous metabolic studies
[30,31]. The documentation of gene expression differ-
ences along signaling and metabolic pathways is impor-
tant in compound screening during the drug discovery
process. Compounds may affect significantly altered path-
ways between cell lines and tumor tissue differently.
Recent studies are taking advantage of the technological
advances in microfluidics and tissue engineering to
develop three-dimensional cell culture systems that aim
simulating in vivo culture conditions. Whether cell lines
can be made to mimic tumor cell gene expression patterns
by altering the culture medium conditions is a question
yet to be fully explored.
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